TEL AVIV, Israel, March 25 /PRNewswire/ -- BSP Ltd. (http://www.bsp.co.il/pressall.asp), an Israeli company which develops and markets systems for non-invasive diagnosis and monitoring of ischemic heart disease, will be launching their HyperQ(TM) Stress System in the US during the 57th Annual ACC 08 Meeting in Chicago, IL.
The HyperQ(TM) is cutting-edge technology implemented in an innovative stress-test system, offering highly reliable, low-cost and risk free cardiac monitoring for broad populations and allows, for the first time, effective and accurate testing for Ischemic heart disease patients.
The HyperQ(TM) system received FDA clearance (510K), as well as the European CE marking. To date, more than 3500 patients in Israel, Europe and the US have been examined by HyperQ(TM) Stress Systems in controlled clinical studies, pilot programs and routine testing in the setting of private offices and hospital clinics. The results have demonstrated the system's high efficiency and unmatched accuracy in the diagnosis of IHD.
The company has entered the clinical and commercial phase, during which the HyperQ(TM) Stress System will be integrated in inpatient settings, outpatient cardiology departments, private doctor offices and major research centers.
Further applications on the company's scope, based on the same core technology, include bedside monitors for ischemic events; devices for cardiac home-care and telemedicine; periodic check-up systems, and the implementation of the HyperQ(TM) technology in implantable cardiac devices such as pacemakers and defibrillators.
Dr. Amir Beker, CEO of BSP says, "BSP's HyperQ(TM) technology is a revolutionary solution to today's most fatal pathology. The HyperQ(TM) Stress System is a non-invasive solution that will improve the standard of care for cardiac patients and at the same time will help reduce unnecessary costly and potentially harmful procedures. The HyperQ(TM) Stress System thus addresses dire needs of private and national healthcare systems to balance the immense costs of cardiac diagnosis and monitoring, while decreasing the risk of further, often invasive, tests for cardiac patients".
BSP is dedicated to providing novel, risk free and highly reliable solutions for the diagnosis and monitoring of Ischemic Heart Disease. BSP was founded in 2000 by Dr. Amir Beker and Mr. Ariel Landau and has completed a successful IPO in mid-2006 and its shares are traded on the Tel Aviv Stock Exchange.
Contact: Dr. Amir Beker, +972-3-6474840, http://www.bspmedical.com
|SOURCE BSP - Biological Signal Processing Ltd|
Copyright©2008 PR Newswire.
All rights reserved